In terms of long-term follow-up of BC patients, a recently published study of clinical interest highlighted a significant challenge by showing that IL-17 remains significantly elevated in patients with early-stage BC even after adjuvant chemotherapy and endocrine therapy, suggesting that new solutions are needed [221]. The gene discussed is IL17A; the disease is breast cancer.